/Vertex%20Pharmaceuticals%2C%20Inc_%20HQ%20in%20Boston-by%20Tada%20Images%20via%20Shuttershock.jpg)
Vertex Pharmaceuticals Incorporated (VRTX) is a leading U.S. biopharmaceutical company, headquartered in Boston, Massachusetts, deeply committed to discovering and developing transformative therapies for serious diseases. Vertex is best known for its pioneering work in cystic fibrosis (CF) with blockbuster drugs like Trikafta, Kalydeco, Orkambi, and others in its commercial portfolio. Beyond CF, its pipeline spans treatments for pain, sickle cell disease, kidney disorders, and type 1 diabetes. Vertex’s market cap is around $111.3 billion.
Shares of the biopharma giant have underperformed the broader market. Over the past 52 weeks, VRTX stock has slipped 6.8%, while the broader S&P 500 Index ($SPX) has gained 13.7%. Although the stock surged 7.8% on a year-to-date (YTD) basis, it still lagged behind SPX’s 13.4% gains.
